Histomorphometric Evaluation of Socket Preservation Healing Using Xenogeneic Bone Substitute Combined with Statin: A Prospective Split-Mouth Clinical Pilot Study Authors: Tomislav Katanec, Luka Šimunović, Robert Likić, Igor Smojver, Stjepanka Lešić, Ivica Pelivan, Dragana Gabrić Published: 2026 ABSTRACT ObjectiveStatins exhibit pleiotropic effects on bone metabolism, including osteogenic and angiogenic activity. The aim of this pilot study was to evaluate whether local application of simvastatin combined with a bovine-derived xenogeneic bone substitute enhances histomorphometric outcomes of socket preservation compared with the bone substitute alone after a three-month healing period.Materials and MethodsThis prospective split-mouth clinical study included nine patients requiring bilateral tooth extraction. One socket was treated with cerabone® plus alone (control), while the contralateral socket received cerabone® plus combined with locally applied simvastatin (1 mg/0.2 mL saline). Bone core biopsies were harvested three months after grafting and analyzed histomorphometrically. The proportions of newly formed bone (NB/TV), residual bone substitute material (BSM/TV), and connective tissue (CT/TV) were quantified. Paired t-tests and Wilcoxon signed-rank tests were used for statistical analysis.ResultsHistomorphometric analysis demonstrated a similar tissue composition in both groups. Connective tissue represented the predominant component in the control and statin-treated sites (59.1 ± 12.0% and 64.3 ± 9.4%, respectively; p = 0.31). Newly formed bone accounted for 31.0 ± 15.5% in the control group and 26.2 ± 11.6% in the statin group (p = 0.45). Residual bone substitute material showed comparable values between groups (9.9 ± 8.5% vs. 9.5 ± 9.7%; p = 0.91). No statistically significant differences were observed.ConclusionsThe addition of locally applied simvastatin to a bovine-derived xenogeneic bone substitute did not result in significant histomorphometric differences in socket preservation after three months. At the tested dose and delivery method, simvastatin did not enhance early mineralized tissue formation compared with the bone substitute alone. Introduction Bone regeneration is a key objective in oral and maxillofacial surgery, particularly in alveolar ridge preservation and socket grafting before implant placement (1-5). Xenogeneic bovine-derived bone substitutes, such as high-temperature sintered bovine bone combined with hyaluronic acid (e.g., cerabone® plus), provide a stable scaffold for osteoconduction and volume maintenance; however, fast and robust new bone formation remains challenging to achieve. (6-8). To enhance osteogenesis, several pharmacological adjuncts have been explored. Among these, statins—3-hydroxy-3-methyl-coenzyme A (HMG-CoA) reductase inhibitors, initially developed for lipid lowering, have shown pleiotropic effects on bone, including stimulation of osteogenesis and angiogenesis (9-11). Initial screening of over 30,000 compounds identified the statins lovastatin and simvastatin as stimulators of the bone morphogenetic protein-2 (BMP-2) promoter (12). Subsequent in-vitro studies demonstrated that statins such as simvastatin up-regulate BMP-2, activate the Ras/PI3K/Akt/ERK pathway and enhance osteoblast differentiation and viability (13). Among available statins, simvastatin was chosen for this study due to its lipophilic nature, which allows better tissue penetration and cellular uptake compared with hydrophilic statins (e.g., pravastatin) (14, 15). Moreover, preclinical studies have demonstrated that local simvastatin application at low milligram concentrations can enhance bone formation in calvarial and mandibular defects without inducing local toxicity or inflammation. These pharmacokinetic and biological characteristics make simvastatin a suitable candidate for local delivery in bone regenerative procedures (16-19). Given these biological properties, the working hypothesis of this study was that locally applied simvastatin combined with a bovine-derived xenograft (Cerabone® Plus) would modulate the early healing microenvironment, potentially enhancing angiogenic and osteogenic activity, and thereby influence early histomorphometric outcomes at 3 months. In vivo, local application of statins has been shown to increase bone formation in calvarial or mandibular animal models, with one study demonstrating increased BMP-2, nitric oxide (NO) and bone formation rate following local simvastatin placement in rats (20). Observational human studies also suggest a potential association between statin use and improved bone mineral density or reduced fracture risk, although the results are heterogeneous (21). From a biomaterials standpoint, combining graft materials with pharmacologic agents to achieve synergistic effects — scaffold (osteoconduction) plus drug (osteoinduction) — remains an attractive strategy in bone regeneration. Recent reviews highlight that while statin-loaded biomaterials have shown promising in preclinical models, “translational barriers” remain: optimal statin dose, delivery kinetics, carrier interaction and human evidence are still lacking (22-24). Recent clinical and translational evidence highlights continued interest in combining biomaterials with pharmacologic agents to enhance bone regeneration. Studies evaluating xenogeneic grafts enriched with bioactive molecules have reported variable effects depending on carrier properties, release kinetics, and defect characteristics (2, 3). Similarly, systematic assessments of drug–biomaterial combinations emphasize the importance of dose optimisation and controlled delivery systems for achieving predictable osteogenic responses (23). Despite promising preclinical data, the translational relevance of locally delivered statins remains uncertain due to inconsistent clinical outcomes, heterogeneous dosing strategies, and lack of pharmacokinetic characterisation. Consequently, small-scale clinical pilot studies are needed to explore feasibility, safety, and preliminary biological effects prior to larger controlled trials. Given this background, the present study aimed to evaluate whether the local application of a statin combined with a bovine-derived xenograft (cerabone® plus) in a split-mouth clinical design would enhance histomorphometric parameters of alveolar bone regeneration compared with the graft alone. Specifically, we assessed residual graft material (BSM/TV %), newly formed bone (NB/TV %) and soft-tissue fraction (CT/TV %) at 3 months. A 3-month healing interval was selected because this reflects the early stage of xenograft integration commonly used for implant site evaluation and corresponds to the standard timeline for biopsy retrieval in clinical studies of socket preservation. For all histomorphometric parameters, TV denotes total tissue volume, comprising mineralised bone, residual graft material, and non-mineralised connective tissue. Materials and Methods Study Design This prospective split-mouth clinical study investigated the histomorphometric characteristics of bone regeneration following preservation with cerabone® plus (Botiss Biomaterials GmbH, Zossen, Germany), with and without the addition of locally applied simvastatin (Simvastatin, Calbiochem, San Diego, CA, USA). Each patient received two grafts: one placed in a scheduled extraction socket designated as the control site, and the contralateral socket in the opposing quadrant designated as the experimental site, allowing intra-patient comparison under identical biological conditions. Randomization was performed using a computer-generated random sequence (www.randomizer.org) by an independent investigator not involved in the surgical or analytical procedures. Allocation was concealed until the time of graft preparation. All procedures were performed in accordance with the Declaration of Helsinki (2013) and approved by the School of Dental Medicine University of Zagreb Ethics Committee (approval no. 05 – PA-30-III-12/2021.). All participants signed written informed consent prior to enrolment. Patient Population and Surgical Procedure Nine adult patients (five females, four males) aged 29 to 79 years (mean 56 years) requiring extraction of two non-adjacent teeth located in contralateral quadrants of the same jaw, enabling a split-mouth comparison, were enrolled. All participants were systemically healthy (ASA I–II) and had no history of metabolic bone disease, bisphosphonate or corticosteroid therapy, or systemic statin use (Table 1). Moreover, all patients presented with good periodontal health, with no untreated periodontitis, active infection, or suppuration at the time of surgery. Table 1Demographic and clinical characteristics of the study population and site allocation.No.SexAgeTooth/RegionControlTooth/RegionExperimental1Female6416Cerabone® Plus26Cerabone® Plus + Statin2Female7916Cerabone® Plus26Cerabone® Plus + Statin3Male6016Cerabone® Plus26Cerabone® Plus + Statin4Male4515Cerabone® Plus26Cerabone® Plus + Statin5Female2816Cerabone® Plus26Cerabone® Plus + Statin6Male5516Cerabone® Plus26Cerabone® Plus + Statin7Male7016Cerabone® Plus26Cerabone® Plus + Statin8Female4546Cerabone® Plus26Cerabone® Plus + Statin9Male2916Cerabone® Plus26Cerabone® Plus + Statin Demographic and clinical characteristics of the study population and site allocation. All extraction sites exhibited intact socket morphology at baseline. The buccal plate was preserved in all cases, as were the remaining alveolar walls. No signs of periodontal inflammation were present around the post-extraction alveolus. In cases where tooth extraction was indicated due to a chronic periapical (ostitic) process, the pathological lesion was completely removed together with its surrounding shell, and only the sites with intact bony walls after thorough debridement were included in the study. The average mesio-distal width of the post-extraction alveolus was approximately 10–11 mm, while the bucco-oral width ranged from 11–12 mm, indicating comparable socket dimensions across sites. Atraumatic tooth extractions were performed under local anaesthesia (articaine 4% + epinephrine 1:100,000; Septodont, France). Atraumatic extraction was performed using periotomes and fine luxators (Hu-Friedy, Chicago, USA) without raising a flap, in order to preserve socket walls and minimise trauma. Following the socket debridement, the grafting procedure was randomised per side: Control site: cerabone® plus granules (0.5–1 mm; Botiss Biomaterials GmbH, Zossen, Germany) hydrated in sterile saline. Experimental site: cerabone® plus combined with simvastatin (Simvastatin, Calbiochem, USA) 1 mg in 0.2 mL saline immediately before placement. The 1 mg simvastatin dose used in this study represents a low local concentration previously shown to be biologically active in preclinical calvarial and mandibular models, while remaining below thresholds associated with local cytotoxicity or inflammatory reactions (15-18). All grafts were covered with a resorbable collagen membrane (Jason® membrane, Botiss Biomaterials GmbH, Zossen, Germany) and closed primarily with 4-0 monofilament sutures. Postoperative care included amoxicillin 500 mg three times daily for 5 days and 0.12% chlorhexidine rinses twice daily for 1 week. Clinical follow-up was performed at 7 days, 1 month, and 3 months postoperatively to assess healing and detect potential complications such as soft tissue dehiscence, membrane exposure, infection, graft loss, or adverse tissue reactions. Healing was uneventful in all cases. At 7 days, soft-tissue closure, absence of dehiscence, and membrane coverage were evaluated and sutures were removed. At 1 month, mucosal maturation and ridge contour stability were assessed. At 3 months, sites were re-evaluated clinically before biopsy retrieval. Biopsy Retrieval and Tissue Processing At 3 months post-grafting, bone core biopsies (Ø 2 mm, length 8 mm) were harvested from the center of the preserved socket during implant site preparation using a trephine bur under copious sterile saline irrigation. Biopsy retrieval was performed without flap elevation, through the healed mucosa, to minimize additional trauma and maintain the integrity of the regenerated site. The depth of 8 mm corresponded to the planned implant length and ensured sampling of the entire regenerated compartment while avoiding perforation of the native bone floor. Samples were fixed in 10% neutral buffered formalin, dehydrated in graded ethanol, and embedded in methyl methacrylate to preserve mineralised architecture. Trephine bur (Ø 2 mm, Hager & Meisinger GmbH, Neuss, Germany) was used for retrieval. Sections (~50 µm thick) were cut using a microtome (Leica SP1600, Leica Microsystems, Germany), and staining was performed using toluidine blue and Masson’s trichrome kits (Sigma-Aldrich, USA). All samples were coded and analysed in a blinded fashion. Histomorphometric Analysis The histomorphometric evaluation was performed according to established protocols (24). Digitised slides were obtained using a light microscope (Axio Scope.A1, Zeiss) with a digital camera (Axiocam 105, Zeiss), a motorised stage, and ZEN Core v3.0 software for panoramic scans. Quantitative histomorphometry measured the percentage of NB/TV, BSM/TV, and CT/TV. Analyses were performed using ZEN Core and verified in ImageJ v1.53 (NIH, Bethesda, USA); three systematically selected high-magnification fields per section were averaged per specimen. Fields were selected using a systematic uniform random sampling protocol. The analysed area per field measured 1.2 mm2. Inter-observer reliability was assessed in 20% of samples and demonstrated excellent agreement (ICC > 0.90). Statistical Analysis All statistical analyses were performed at the patient level (n = 9 pairs) in accordance with the split-mouth study design. Continuous variables are presented as mean ± standard deviation (SD). Normality was assessed on the distribution of paired differences (experimental minus control) using the Shapiro–Wilk test. No statistically significant deviations from normality were detected for NB/TV, BSM/TV, or CT/TV (p > 0.05 for all comparisons), supporting the use of parametric testing. Primary comparisons between control (Cerabone® Plus) and experimental (Cerabone® Plus + Statin) sites were performed using paired t-tests. Given the small paired sample size and the limited power of normality testing in small datasets, Wilcoxon signed-rank tests were additionally conducted to confirm the robustness of the findings. Non-parametric analyses yielded results consistent with parametric testing for all evaluated outcomes. For each parameter, mean differences, 95% confidence intervals (CIs), and standardized effect sizes (Cohen’s d for paired samples) were calculated to quantify the magnitude and precision of treatment effects. Statistical significance was defined as p < 0.05 (two-tailed). As this investigation was designed as an exploratory pilot study, no a priori sample size calculation was performed. Therefore, inferential results should be interpreted cautiously and primarily as hypothesis-generating, intended to inform effect-size estimation and sample-size planning for future confirmatory trials. All analyses were conducted using IBM SPSS Statistics version 29.0.1.0 (IBM Corp., Armonk, NY, USA). Results Nine patients (five females, four males; mean age 56 ± 17 years, range 29–79 years) completed the study. Each participant contributed two grafted sites (control and experimental), resulting in a total of 18 biopsy specimens for analysis (Table 1). All surgical procedures were uneventful, with no intra- or postoperative complications, inflammation, or graft exposure observed. Postoperative healing was satisfactory in all cases, and all sites demonstrated clinically stable soft-tissue coverage and adequate ridge contour at the time of biopsy retrieval (three months post-grafting). No systemic or local adverse effects related to statin application were reported. The histomorphometric evaluation demonstrated a consistent and reproducible pattern of tissue distribution in both treatment modalities (Figure 1). No statistically significant inter-individual variation was detected between the Cerabone® Plus and Cerabone® Plus + Statin groups. Representative histological sections of the Cerabone® Plus + Statin (A) and Cerabone® Plus (B) sites at three months (HE, 100×; scale bar = 50 µm). Newly formed bone (NB) is apposed to Cerabone® granules (CB), demonstrating osseointegration. Red arrows indicate blood vessels supporting revascularization, and green arrows highlight osteoblast seams at NB/CB interfaces. A gradual transition from connective tissue (CT) to NB reflects progressive tissue maturation. Across all samples, connective tissue (CT) represented the predominant tissue component, followed by newly formed bone (NB) and residual bone substitute material (BSM). Quantitatively, CT accounted for approximately 59 ± 12% of the total tissue in the control group and 64 ± 9% in the Cerabone® Plus + Statin group. The difference between groups was not statistically significant (p = 0.31; Cohen’s d = –0.36), but a trend toward higher CT fraction (~5%) in the Cerabone® Plus + Statin group was observed. The relative proportions of NB/TV and BSM/TV were also similar between treatments. NB/TV represented 31.0 ± 15.5% in the Cerabone® Plus group and 26.2 ± 11.6% in the Cerabone® Plus + Simvastatin group, with no significant difference between groups (p = 0.45; Cohen’s d = 0.27). BSM/TV constituted approximately 10% of the total tissue volume in both conditions (9.9 ± 8.5% vs. 9.5 ± 9.7%), indicating comparable graft resorption behavior at the 3-month interval (Table 2, Figure 1). Table 2Histomorphometric outcomes (mean ± SD, 95% confidence intervals, p-values, and effect sizes) for control (Cerabone® Plus) and experimental (Cerabone® Plus + Statin) sites at three months. Parameter Group Mean ± SD (%) 95% CI of the difference Paired t-test p-value Wilcoxon p-value Cohen’s d Newly formed bone (NB/TV) Cerabone® Plus31.0 ± 15.5[–8.7, 18.4]0.450.5940.27Cerabone® Plus + Statin26.2 ± 11.6 Residual bone substitute (BSM/TV) Cerabone® Plus9.9 ± 8.5[–6.3, 7.1]0.910.8890.03Cerabone® Plus + Statin9.5 ± 9.7 Connective tissue (CT/TV) Cerabone® Plus59.1 ± 12.0[–16.2, 5.3]0.310.441–0.36Cerabone® Plus + Statin64.3 ± 9.4Data are presented as mean ± standard deviation (SD), with 95% confidence intervals (CI) and effect sizes (Cohen’s d) calculated for paired comparisons. No statistically significant differences were observed between groups Histomorphometric outcomes (mean ± SD, 95% confidence intervals, p-values, and effect sizes) for control (Cerabone® Plus) and experimental (Cerabone® Plus + Statin) sites at three months. Data are presented as mean ± standard deviation (SD), with 95% confidence intervals (CI) and effect sizes (Cohen’s d) calculated for paired comparisons. No statistically significant differences were observed between groups Collectively, these data indicate that while statin addition did not significantly modify the quantitative tissue composition, it preserved the normal healing pattern observed with Cerabone® Plus alone. The modest (~5%) increase in CT/TV observed in the Cerabone® Plus + Statin sites may reflect a transient early-stage soft-tissue predominance rather than reduced osteogenic activity, which is consistent with known early angiogenic/fibroblastic effects of statins. Discussion This clinical split-mouth pilot study evaluated the effect of adding locally applied simvastatin to a bovine-derived xenograft (Cerabone® Plus) on alveolar bone regeneration following socket preservation. The quantitative histomorphometric analysis at three months revealed no statistically significant differences in NB/TV, BSM/TV, or CT/TV between Cerabone® Plus and Cerabone® Plus + Statin sites. Nevertheless, a consistent intra-individual trend toward a slightly higher CT/TV fraction (~5%) was observed in the Cerabone® Plus + Statin group. Although not statistically significant, this subtle shift is biologically plausible and may reflect early modulation of fibrovascular tissue rather than a clear osteoanabolic effect. The present findings align with preclinical and translational data indicating that statins exert complex, dose- and carrier-dependent effects on bone formation. Mundy et al. (26) first identified statins as stimulators of the BMP-2 promoter, linking HMG-CoA reductase inhibition to osteoanabolic signalling. Subsequent animal and biomaterial studies have shown that local statin delivery can increase bone formation and neovascularisation, but that the magnitude and duration of response depend on the statin type, concentration, and delivery system. Recent reviews have highlighted that statin-loaded scaffolds, hydrogels, and microspheres can enhance osteogenesis and angiogenesis when sustained local levels are achieved, yet translation to predictable clinical benefit remains challenging (23, 24, 27, 28). In humans, data remain inconsistent. While systemic statin use has been associated with beneficial skeletal effects, controlled local-delivery studies show variable outcomes. Randomized clinical trials of locally delivered simvastatin in periodontal intrabony defects have reported mixed results: some demonstrated adjunctive gains in clinical attachment or radiographic fill, whereas others showed no significant benefit, particularly in anatomically constrained lesions. More recent clinical trials and systematic reviews confirm that local statin efficacy depends strongly on dose, carrier, defect morphology, and release kinetics (29, 30). Meta-analytic syntheses likewise indicate that local statins can improve certain periodontal parameters, yet effect sizes vary considerably across studies (31, 32). A recent systematic review focusing on socket healing after tooth extraction suggested potentially favorable outcomes with local simvastatin, though substantial methodological heterogeneity persists (33). In the current study, bone formation occurred predictably in both groups, with NB/TV constituting approximately 30% of the total tissue and BSM/TV around 10%. These proportions are broadly consistent with reports in the literature regarding slowly resorbing xenogeneic bovine grafts at early healing stages, where limited graft resorption and moderate new bone formation are expected (25, 34). The similarity between Cerabone® Plus and Cerabone® Plus + Statin sites indicates that the simvastatin dose and release profile achieved with simple mixing did not substantially modulate osteogenic activity within the three-month interval. The low resorption rate and compact pore architecture typical of this class of xenografts may have further restricted drug diffusion to osteogenic cells within the defect (35, 36). The modest increase in CT/TV in simvastatin-treated sites, although not statistically significant, warrants mechanistic consideration. Statins are known to enhance angiogenesis and fibroblast proliferation through up-regulation of VEGF, eNOS, and hypoxia-inducible factor-1α pathways, and these pleiotropic effects may initially favour a fibrovascular tissue phenotype (37). In the context of bone healing, such vascular activation typically precedes mineralisation; therefore, a higher CT/TV fraction at three months may represent an intermediate phase of enhanced granulation or fibrovascular tissue rather than a definitive impairment of bone formation. Similar early-phase increases in soft tissue have been described in statin-loaded scaffolds that subsequently support improved bone regeneration once mineralisation progresses (10, 38-40). From a pharmacological standpoint, these results reinforce that statin effects in bone are highly context-dependent and critically influenced by the delivery system. Osteoanabolic activity mediated by BMP-2 up-regulation generally requires sustained local statin concentrations in the low micromolar range (27, 41), whereas angiogenic or anti-inflammatory responses can occur at lower doses. Simple admixture of simvastatin with a dense, slowly resorbing xenograft such as Cerabone® Plus is unlikely to provide controlled release, and the drug may be rapidly cleared from the defect or sequestered within the graft surface. Recent experimental work has shown that statin effects are markedly attenuated when delivered without an appropriate drug-delivery system and can be prolonged when incorporated into hydrogels, polymeric membranes, or microsphere-based carriers (42-45). Taken together, the current data suggest that simply mixing simvastatin with a xenogeneic bone graft is unlikely to elicit measurable osteogenic enhancement at three months. Future translational efforts should prioritise delivery platforms that provide sustained, spatially controlled release, such as polymeric microspheres, smart hydrogels, electrospun membranes, or aerogel scaffolds, while maintaining the structural advantages of xenogeneic grafts (46). Integration of histomorphometry with molecular markers of angiogenesis and osteogenesis (e.g., VEGF, BMP-2, osteocalcin) and advanced imaging (micro-CT or cone-beam CT) would allow a more complete characterisation of the temporal tissue response and help distinguish transient soft-tissue modulation from durable bone formation. This study has several limitations that must be acknowledged. First, as a pilot trial with nine patients, the sample size is small and underpowered to detect small-to-moderate differences between treatments; the resulting wide confidence intervals mean that all statistical comparisons should be interpreted cautiously and considered exploratory. Second, although the split-mouth design reduces inter-individual variability, it does not eliminate potential confounders such as site-specific anatomy or local vascular conditions. Third, no molecular or immunohistochemical markers of osteogenesis or angiogenesis (e.g., BMP-2, VEGF, osteocalcin) were evaluated, which limits mechanistic interpretation of the observed CT/TV shift. Fourth, the local pharmacokinetics of simvastatin release from Cerabone® Plus were not quantified, hence the actual drug concentration and residence time at the healing site remain unknown. Finally, the three-month endpoint represents an early healing stage; sequential or long-term assessments could better capture the temporal evolution of statin-mediated effects. Additionally, the use of a single centrally harvested 2-mm trephine biopsy may not fully represent the spatial heterogeneity of tissue composition within the entire regenerated socket. Regional coronal-apical or peripheral variations in mineralised and non-mineralised tissue distribution could therefore remain undetected, potentially influencing quantitative histomorphometric outcomes. Despite these limitations, the present pilot study provides preliminary clinical evidence that adding 1 mg of locally applied simvastatin to Cerabone® Plus is biologically safe and does not adversely affect socket preservation outcomes at three months. Within the constraints of the small sample size and early endpoint, the combination appears histologically neutral, with a possible trend toward greater CT/TV that may reflect early fibrovascular modulation rather than a definitive change in NB/TV. Larger, rigorously designed clinical trials incorporating optimised delivery systems, pharmacokinetic assessment, advanced imaging, and molecular endpoints are warranted to clarify whether local statins can be harnessed as reliable osteoanabolic adjuncts in alveolar ridge preservation and other bone regenerative procedures. Conclusion Within the limitations of this pilot split-mouth clinical study, the local application of 1 mg simvastatin combined with Cerabone® Plus did not produce measurable improvements in histomorphometric bone regeneration at the 3-month healing interval. Both treatment groups exhibited comparable NB/TV and BSM/TV values, indicating that simvastatin at the tested dose and delivery method did not enhance mineralised tissue formation or graft resorption during early healing. A modest increase in CT/TV observed in simvastatin-treated sites may reflect transient early fibrovascular or angiogenic activity rather than a definitive alteration in osteogenesis at this stage. Overall, the findings suggest that simple admixture of simvastatin with a slowly resorbing xenograft is biologically safe but histologically neutral at three months. Future research should investigate controlled-release delivery platforms, optimise dosing strategies, and integrate molecular or imaging-based parameters to clarify the temporal and mechanistic effects of locally applied statins in clinical bone regeneration. Larger, well-powered clinical trials are required before firm conclusions regarding efficacy can be established.